Theranostics in precision medicine integrating diagnosis and targeted therapy through nanotechnology and molecular imaging

Read full text Summarise with VIRAT
Authors: Dornala Chaitanya Dixit, N Lahari, M. Srirama Chandra
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Theranostics represents a transformative approach in precision medicine, integrating diagnostic imaging (PET, SPECT, MRI, CT) with targeted therapy to offer personalized medical care, primarily in oncology. Emerging from nuclear medicine, this unified strategy uses nanotechnology to create multifunctional platforms, such as liposomes and gold nanoparticles that enable the simultaneous delivery of imaging and therapeutic agents. These nanotheranostics are designed for precise detection and characterization of disease-specific molecular markers, allowing for active or passive targeting, optimized dosing, minimized systemic toxicity, and real-time monitoring. By merging diagnosis and treatment into a dynamic, single approach, theranostics, including types like radiotheranostics and optotheranostics, enhances clinical outcomes, ensures accurate patient stratification, and holds significant potential for “improving care across various complex diseases, including neurological and cardiovascular disorders”. Electron Paramagnetic Resonance (EPR) spectroscopy detects species with unpaired electrons, such as free radicals and transition metals. In theranostics, it characterizes colloidal carriers, phase transitions, and drug-membrane interactions, complementing nanotechnology-based imaging.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Nanoparticle-Based Drug Delivery Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
International Journal of Pharmacy and Pharmaceutical Science
Volume
8
Issue
2
Pages
47–53
Publication date
1 February 2026
Language
EN